Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,087 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement.
Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid-Grendelmeier P, Zuberbier T. Bousquet J, et al. Among authors: canonica gw. Allergy. 2011 Jun;66(6):765-74. doi: 10.1111/j.1398-9995.2011.02590.x. Epub 2011 Apr 18. Allergy. 2011. PMID: 21496059 Review.
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge.
Ciprandi G, Buscaglia S, Pesce G, Passalacqua G, Rihoux JP, Bagnasco M, Canonica GW. Ciprandi G, et al. Among authors: canonica gw. J Allergy Clin Immunol. 1995 Feb;95(2):612-21. doi: 10.1016/s0091-6749(95)70324-1. J Allergy Clin Immunol. 1995. PMID: 7531732 Clinical Trial.
Alternative routes for allergen-specific immunotherapy.
Passalacqua G, Canonica GW. Passalacqua G, et al. Among authors: canonica gw. J Investig Allergol Clin Immunol. 1996 Mar-Apr;6(2):81-7. J Investig Allergol Clin Immunol. 1996. PMID: 8727263 Review.
The clinical safety of H1-receptor antagonists. An EAACI position paper.
Passalacqua G, Bousquet J, Bachert C, Church MK, Bindsley-Jensen C, Nagy L, Szemere P, Davies RJ, Durham SR, Horak F, Kontou-Fili K, Malling HJ, van Cauwenberge P, Canonica GW. Passalacqua G, et al. Among authors: canonica gw. Allergy. 1996 Oct;51(10):666-75. doi: 10.1111/j.1398-9995.1996.tb02109.x. Allergy. 1996. PMID: 8904993 Review. No abstract available.
Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity.
Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Grögen J, Mela GS, Varese P, Bertolini C, Bagnasco M, Canonica GW. Ciprandi G, et al. Among authors: canonica gw. J Allergy Clin Immunol. 1996 Dec;98(6 Pt 1):1088-96. doi: 10.1016/s0091-6749(96)80196-5. J Allergy Clin Immunol. 1996. PMID: 8977510 Clinical Trial.
Seasonal rhinitis and azelastine: long- or short-term treatment?
Ciprandi G, Ricca V, Passalacqua G, Truffelli T, Bertolini C, Fiorino N, Riccio AM, Bagnasco M, Canonica GW. Ciprandi G, et al. Among authors: canonica gw. J Allergy Clin Immunol. 1997 Mar;99(3):301-7. doi: 10.1016/s0091-6749(97)70046-0. J Allergy Clin Immunol. 1997. PMID: 9058684 Clinical Trial.
1,087 results